Addressing Liver Fibrosis with Liposomes Targeted to Hepatic Stellate Cells

References

• Adrian J. E., Poelstra K., Scherphof G. L., Molema G., Meijer D. K. F., Reker-Smit C., Morselt H. W., Kamps J. A. A. M. Interaction of targeted liposomes with primary cultured hepatic stellate cells: Involvement of multiple receptor systems. J. Hepatol. 2006; 44: 560–567
   PubMed Web of Science ®Google Scholar
• Adrian J. E., Kamps J. A. A. M., Scherphof G. L., Meijer D. K. F., van Loenen-Weemaes A. M., Reker-Smit C., Terpstra P., Poelstra K. A novel lipid-based drug carrier targeted to the non-parenchymal cells, including hepatic stellate cells, in the fibrotic livers of bile duct ligated rats. Biochim. Biophys. Acta 2007a; 1768(10)1430–1439
   PubMed Web of Science ®Google Scholar
• Adrian J. E., Poelstra K., Scherphof G. L., Meijer D. K. F., van Loenen-Weemaes A. M., Reker-Smit C., Morselt H. W., Zwiers P., Kamps J. A. A.M. Effects of a new bioactive lipid-based drug carrier on cultured hepatic stellate cells and liver fibrosis in bile duct ligated rats. J. Pharmacol. Exp. Ther. 2007b; 321: 536–543
   PubMed Web of Science ®Google Scholar
• Adrian J. E., Kamps J. A. A. M., Poelstra K., Scherphof G. L., Meijer D. K. F., Kaneda Y. Delivery of viral vectors to hepatic stellate cells in fibrotic livers using HVJ envelops fused with targeted liposomes. J. Drug Target. 2007c; 15: 75–82
   PubMed Web of Science ®Google Scholar
• Aleynik S. I., Leo M. A., Ma X., Aleynik M. K., Lieber C. S. Polyenylphosphatidylcholine prevents carbon tetrachloride-induced lipid peroxidation while it attenuates liver fibrosis. J. Hepatol. 1997; 27: 554–561
   PubMed Web of Science ®Google Scholar
• Allen T. M., Cullis P. R. Drug delivery systems: entering the mainstream. Science 2004; 303: 1818–1822
   PubMed Web of Science ®Google Scholar
• Andiran F., Ayhan A., Tanyel F. C., Abbasoglu O., Sayek I. Regenerative capacities of normal and cirrhotic livers following 70% hepatectomy in rats and the effect of alpha-tocopherol on cirrhotic regeneration. J. Surg. Res. 2000; 89: 184–188
   PubMed Web of Science ®Google Scholar
• Austin A. S., Mahida Y. R., Clarke D., Ryder S. D., Freeman J. G. A pilot study to investigate the use of oxpentifylline (pentoxifylline) and thalidomide in portal hypertension secondary to alcoholic cirrhosis. Aliment Pharmacol. Ther. 2004; 19: 79–88
   PubMed Web of Science ®Google Scholar
• Bataller R., Brenner D. A. Liver fibrosis. J. Clin. Invest. 2005; 115: 209–218
   PubMed Web of Science ®Google Scholar
• Beljaars L., Molema G., Schuppan D., Geerts A., De Bleser P. J., Weert B., Meijer D. K., Poelstra K. Successful targeting to rat hepatic stellate cells using albumin modified with cyclic peptides that recognize the collagen type VI receptor. J. Biol. Chem. 2000; 275: 12743–12751
   PubMed Web of Science ®Google Scholar
• Beljaars L., Molema G., Weert B., Bonnema H., Olinga P., Groothuis G. M., Meijer D. K. F., Poelstra K. Albumin modified with mannose 6-phosphate: A potential carrier for selective delivery of antifibrotic drugs to rat and human hepatic stellate cells. Hepatology 1999; 29: 1486–1493
   PubMed Web of Science ®Google Scholar
• Beljaars L., Olinga P., Molema G., de Bleser P., Geerts A., Groothuis G. M., Meijer D. K., Poelstra K. Characteristics of the hepatic stellate cell-selective carrier mannose 6-phosphate modified albumin (M6P(28)-HSA. Liver 2001; 21: 320–328
   PubMedGoogle Scholar
• Beljaars L., Weert B., Geerts A., Meijer D. K. F., Poelstra K. The preferential homing of a platelet derived growth factor receptor-recognizing macromolecule to fibroblast-like cells in fibrotic tissue. Biochem. Pharmacol. 2003; 66: 1307–1317
   PubMed Web of Science ®Google Scholar
• Benyon R. C., Arthur M. J. Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis. 2001; 21: 373–384
   PubMed Web of Science ®Google Scholar
• Bickel M., Baringhaus K. H., Gerl M., Gunzler V., Kanta J., Schmidts L., Stapf M., Tschank G., Weidmann K., Werner U. Selective inhibition of hepatic collagen accumulation in experimental liver fibrosis in rats by a new prolyl 4-hydroxylase inhibitor. Hepatology 1998; 28: 404–411
   PubMed Web of Science ®Google Scholar
• Bruck R., Genina O., Aeed H., Alexiev R., Nagler A., Avni Y., Pines M. Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats. Hepatology 2001; 33: 379–386
   PubMed Web of Science ®Google Scholar
• Castano G., Viudez P., Riccitelli M., Sookoian S. A randomized study of losartan vs propranolol: Effects on hepatic and systemic hemodynamics in cirrhotic patients. Ann. Hepatol. 2003; 2: 36–40
   PubMedGoogle Scholar
• Croquet V., Moal F., Veal N., Wang J., Oberti F., Roux J., Vuillemin E., Gallois Y., Douay O., Chappard D., Cales P. Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension. J. Hepatol. 2002; 37: 773–780
   PubMed Web of Science ®Google Scholar
• De B. K., Bandyopadhyay K., Das T. K., Das D., Biswas P. K., Majumdar D., Mandal S. K., Ray S., Dasgupta S. Portal pressure response to losartan compared with propranolol in patients with cirrhosis. Am. J. Gastroenterol. 2003; 98: 1371–1376
   PubMed Web of Science ®Google Scholar
• De Bleser P. J., Jannes P., Buul-Offers S. C., Hoogerbrugge C. M., van Schravendijk C. F., Niki T., Rogiers V., van den Brande J. L., Wisse E., Geerts A. Insulinlike growth factor-II/mannose 6-phosphate receptor is expressed on CCl4-exposed rat fat-storing cells and facilitates activation of latent transforming growth factor-beta in cocultures with sinusoidal endothelial cells. Hepatology 1995; 21: 1429–1437
   PubMed Web of Science ®Google Scholar
• De Bleser P. J., Niki T., Rogiers V., Geerts A. Transforming growth factor-beta gene expression in normal and fibrotic rat liver. J. Hepatol. 1997; 26: 886–893
   PubMed Web of Science ®Google Scholar
• Dekel R., Zvibel I., Brill S., Brazovsky E., Halpern Z., Oren R. Gliotoxin ameliorates development of fibrosis and cirrhosis in a thioacetamide rat model. Dig. Dis. Sci. 2003; 48: 1642–1647
   PubMed Web of Science ®Google Scholar
• Di Sario A., Bendia E., Taffetani S., Marzioni M., Candelaresi C., Pigini P., Schindler U., Kleemann H. W., Trozzi L., Macarri G., Benedetti A. Selective Na + /H + exchange inhibition by cariporide reduces liver fibrosis in the rat. Hepatology 2003; 37: 256–266
   PubMed Web of Science ®Google Scholar
• Friedman S. L. Liver fibrosis- from bench to bedside. J. Hepatol. 2003; 38: S38–S53
   PubMed Web of Science ®Google Scholar
• Friedman S. L., Bansal M. B. Reversal of hepatic fibrosis. Fact of fantasy?. Hepatology 2006; 43: S82–S88
   PubMed Web of Science ®Google Scholar
• Galli A., Crabb D. W., Ceni E., Salzano R., Mello T., Svegliati-Baroni G., Ridolfi F., Trozzi L., Surrenti C., Casini A. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 2002; 122: 1924–1940
   PubMed Web of Science ®Google Scholar
• Gonzalo T., Talman E. G., van de Ven A., Temming K., Greupink R., Beljaars L., Reker-Smit C., Meijer D. K., Molema G., Poelstra K., Kok R. J. Selective targeting of pentoxifylline to hepatic stellate cells using a novel platinum-based linker technology. J. Control. Release 2006; 111: 193–203
   PubMed Web of Science ®Google Scholar
• Greupink R., Bakker H. I., Bouma W., Reker-Smit C., Meijer D. K., Beljaars L., Poelstra K. The antiproliferative drug doxorubicin inhibits liver fibrosis in bile duct-ligated rats and can be selectively delivered to hepatic stellate cells in vivo. J. Pharmacol. Exp. Ther. 2006; 317: 514–521
   PubMed Web of Science ®Google Scholar
• Greupink R., Bakker H. I., Reker-Smit C., Loenen-Weemaes A. M., Kok R. J., Meijer D. K., Beljaars L., Poelstra K. Studies on the targeted delivery of the antifibrogenic compound mycophenolic acid to the hepatic stellate cell. J. Hepatol. 2005; 43: 884–892
   PubMed Web of Science ®Google Scholar
• Hagens W. I., Olinga P., Meijer D. K., Groothuis G. M., Beljaars L., Poelstra K. Gliotoxin non-selectively induces apoptosis in fibrotic and normal livers. Liver Int. 2006; 26: 232–239
   PubMed Web of Science ®Google Scholar
• Harrison S. A., Torgerson S., Hayashi P., Ward J., Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2003; 98: 2485–2490
   PubMed Web of Science ®Google Scholar
• Hasegawa T., Yoneda M., Nakamura K., Makino I., Terano A. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol. Ther. 2001; 15: 1667–1672
   PubMed Web of Science ®Google Scholar
• Heller J., Trebicka J., Shiozawa T., Schepke M., Neef M., Hennenberg M., Sauerbruch T. Vascular, hemodynamic and renal effects of low-dose losartan in rats with secondary biliary cirrhosis. Liver Int. 2005; 25: 657–666
   PubMed Web of Science ®Google Scholar
• Kaneda Y., Nakajima T., Nishikawa T., Yamamoto S., Ikegami H., Suzuki N., Nakamura H., Morishita R., Kotani H. Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Mol. Ther. 2002; 6: 219–226
   PubMed Web of Science ®Google Scholar
• Kaplan M. M., Cheng S., Price L. L., Bonis P. A. A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results. Hepatology 2004; 39: 915–923
   PubMed Web of Science ®Google Scholar
• Krahenbuhl L., Lang C., Ludes S., Seiler C., Schafer M., Zimmermann A., Krahenbuhl S. Reduced hepatic glycogen stores in patients with liver cirrhosis. Liver Int. 2003; 23: 101–109
   PubMed Web of Science ®Google Scholar
• Krahenbuhl L., Talos C., Reichen J., Krahenbuhl S. Progressive decrease in tissue glycogen content in rats with long-term cholestasis. Hepatology 1996; 24: 902–907
   PubMed Web of Science ®Google Scholar
• Lee E. S., Lee H. E., Shin J. Y., Yoon S., Moon J. O. The flavonoid quercetin inhibits dimethylnitrosamine-induced liver damage in rats. J. Pharm. Pharmacol. 2003; 55: 1169–1174
   PubMed Web of Science ®Google Scholar
• Lieber C. S., Robins S. J., Li J., DeCarli L. M., Mak K. M., Fasulo J. M., Leo M. A. Phosphatidylcholine protects against fibrosis and cirrhosis in the baboon. Gastroenterology 1994; 106: 152–159
   PubMed Web of Science ®Google Scholar
• Lieber C. S., Weiss D. G., Groszmann R., Paronetto F., Schenker S. II. Veterans Affairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease. Alcohol Clin. Exp. Res. 2003; 27: 1765–1772
   PubMed Web of Science ®Google Scholar
• Ma X., Zhao J., Lieber C. S. Polyenylphosphatidylcholine attenuates non-alcoholic hepatic fibrosis and accelerates its regression. J. Hepatol. 1996; 24: 604–613
   PubMed Web of Science ®Google Scholar
• Mato J. M., Camara J., Fernandez de Paz J., Caballeria L., Coll S., Caballero A., Garcia-Buey L., Beltran J., Benita V., Caballeria J., Sola R., Moreno-Otero R., Barrao F., Martin-Duce A., Correa J. A., Pares A., Barrao E., Garcia-Magaz I., Puerta J. L., Moreno J., Boissard G., Ortiz P., Rodes J. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J. Hepatol. 1999; 30: 1081–1089
   PubMed Web of Science ®Google Scholar
• Matsumura Y., Sakaida I., Uchida K., Kimura T., Ishihara T., Okita K. Prolyl 4-hydroxylase inhibitor (HOE 077) inhibits pig serum-induced rat liver fibrosis by preventing stellate cell activation. J. Hepatol. 1997; 27: 185–192
   PubMed Web of Science ®Google Scholar
• Morgan T. R., Weiss D. G., Nemchausky B., Schiff E. R., Anand B., Simon F., Kidao J., Cecil B., Mendenhall C. L., Nelson D., Lieber C., Pedrosa M., Jeffers L., Bloor J., Lumeng L., Marsano L., McClain C., Mishra G., Myers B., Leo M., Ponomarenko Y., Taylor D., Chedid A., French S., Kanel G., Murray N., Pinto P., Fong T. L., Sather M. R. Colchicine treatment of alcoholic cirrhosis: a randomized, placebo-controlled clinical trial of patient survival. Gastroenterology 2005; 128: 882–890
   PubMed Web of Science ®Google Scholar
• Muriel P., Moreno M. G., Hernandez Mdel C., Chavez E., Alcantar L. K. Resolution of liver fibrosis in chronic CCl4 administration in the rat after discontinuation of treatment: effect of silymarin, silibinin, colchicine and trimethylcolchicinic acid. Basic Clin. Pharmacol. Toxicol. 2005; 96: 375–380
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri B. A., Brunt E. M., Wehmeier K. R., Oliver D., Bacon B. R. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003; 38: 1008–1017
   PubMed Web of Science ®Google Scholar
• Nieto N., Cederbaum A. I. S-adenosylmethionine blocks collagen I production by preventing transforming growth factor-beta induction of the COL1A2 promoter. J. Biol. Chem. 2005; 280: 30963–30974
   PubMed Web of Science ®Google Scholar
• Nikolaidis N., Kountouras J., Giouleme O., Tzarou V., Chatzizisi O., Patsiaoura K., Papageorgiou A., Leontsini M., Eugenidis N., Zamboulis C. Colchicine treatment of liver fibrosis. Hepatogastroenterology 2006; 53: 281–285
   PubMed Web of Science ®Google Scholar
• Okuno M., Akita K., Moriwaki H., Kawada N., Ikeda K., Kaneda K., Suzuki Y., Kojima S. Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-beta. Gastroenterology 2001; 120: 1784–1800
   PubMed Web of Science ®Google Scholar
• Pavanato A., Tunon M. J., Sanchez-Campos S., Marroni C. A., Llesuy S., Gonzalez-Gallego J., Marroni N. Effects of quercetin on liver damage in rats with carbon tetrachloride-induced cirrhosis. Dig. Dis. Sci. 2003; 48: 824–829
   PubMed Web of Science ®Google Scholar
• Pinzani M., Gesualdo L., Sabbah G. M., Abboud H. E. Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells. J. Clin. Invest. 1989; 84: 1786–1793
   PubMed Web of Science ®Google Scholar
• Popov Y., Patsenker E., Bauer M., Niedobitek E., Schulze-Krebs A., Schuppan D. Halofuginone induces matrix metalloproteinases in rat hepatic stellate cells via activation of p38 and NFkappaB. J. Biol. Chem. 2006; 281: 15090–15098
   PubMed Web of Science ®Google Scholar
• Raetsch C., Jia J. D., Boigk G., Bauer M., Hahn E. G., Riecken E. O., Schuppan D. Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis. Gut 2002; 50: 241–247
   PubMed Web of Science ®Google Scholar
• Reynaert H., Thompson M. G., Thomas T., Geerts A. Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension. Gut 2002; 50: 571–581
   PubMed Web of Science ®Google Scholar
• Sakaida I., Matsumura Y., Akiyama S., Hayashi K., Ishige A., Okita K. Herbal medicine Sho-saiko-to (TJ-9) prevents liver fibrosis and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. J. Hepatol. 1998; 28: 298–306
   PubMed Web of Science ®Google Scholar
• Shimizu I., Ma Y. R., Mizobuchi Y., Liu F., Miura T., Nakai Y., Yasuda M., Shiba M., Horie T., Amagaya S., Kawada N., Hori H., Ito S. Effects of Sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats. Hepatology 1999; 29: 149–160
   PubMed Web of Science ®Google Scholar
• Sprenger H., Kaufmann A., Garn H., Lahme B., Gemsa D., Gressner A. M. Differential expression of monocyte chemotactic protein-1 (MCP-1) in transforming rat hepatic stellate cells. J. Hepatol. 1999; 30: 88–94
   PubMed Web of Science ®Google Scholar
• Steinbrecher U. P. Receptors for oxidized low density lipoprotein. Biochim. Biophys. Acta 1999; 1436: 279–298
   PubMed Web of Science ®Google Scholar
• Tuncyurek P., Sari M., Firat O., Mutaf I., Gulter C., Tunger A., Yuce G., Yilmaz M., Makay O., Dayangac M., Ersin S. Does pharmaconutrition with L-arginine and/or alpha-tocopherol improve the gut barrier in bile duct ligated rats?. Eur. Surg. Res. 2006; 38: 4–10
   PubMed Web of Science ®Google Scholar
• Wright M. C., Issa R., Smart D. E., Trim N., Murray G. I., Primrose J. N., Arthur M. J., Iredale J. P., Mann D. A. Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology 2001; 121: 685–698
   PubMed Web of Science ®Google Scholar
• Van de Casteele M., Roskams T., Van der Elst I., van Pelt J. F., Fevery J., Nevens F. Halofuginone can worsen liver fibrosis in bile duct obstructed rats. Liver Int. 2004; 24: 502–509
   PubMed Web of Science ®Google Scholar
• Vial P., Riquelme A., Pizarro M., Solis N., Madariaga J. A., Aguayo G., Duarte I., Soza A., Accatino L., Arrese M. Pentoxifylline does not prevent neither liver damage nor early profibrogenic events in a rat model of non-alcoholic steatohepatitis. Ann. Hepatol. 2006; 5: 25–29
   PubMedGoogle Scholar
• Yang Y. Y., Lin H. C., Huang Y. T., Lee T. Y., Hou M. C., Lee F. Y., Liu R. S., Chang F. Y., Lee S. D. Effect of 1-week losartan administration on bile duct-ligated cirrhotic rats with portal hypertension. J. Hepatol. 2002; 36: 600–606
   PubMed Web of Science ®Google Scholar